Article info

Download PDFPDF

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
Free

Authors

  1. Correspondence to Dr Bente Glintborg, The DANBIO registry, Rigshospitalet, and Department of Rheumatology, Gentofte and Herlev University Hospital, Hellerup 2730, Denmark; glintborg{at}dadlnet.dk
View Full Text

Citation

Glintborg B, Loft AG, Omerovic E, et al
To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry

Publication history

  • Received March 26, 2018
  • Revised October 10, 2018
  • Accepted October 16, 2018
  • First published November 5, 2018.
Online issue publication 
January 10, 2019

Article Versions

Related Data

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.